FTC sues big pharmacy benefit managers above insulin selling prices The company brought motion in opposition to Caremark, Specific Scripts and Optum Rx, arguing their “anticompetitive and unfair” rebating techniques “artificially inflated” the list cost of existence-preserving insulin medicine. Pay attention to the short article 10 min This audio is https://kethek.com/